Indivior PLC stock (GB00BYZ0C031): Q1 earnings beat lifts 2026 EPS estimates

Indivior PLC reported first-quarter earnings that exceeded expectations, prompting analysts to raise 2026 EPS forecasts from $3.03 to $3.35 over the past 60 days, according to ad-hoc-news.de as of May 2026.

Indivior PLC, a specialty pharmaceutical firm focused on addiction treatments, delivered Q1 results that beat market consensus, fueling upward revisions in full-year earnings projections. Analysts lifted 2026 EPS estimates to $3.35 from $3.03 in the last 60 days, signaling confidence in the company's pipeline and execution, per ad-hoc-news.de as of May 2026. The stock closed at $38.35 on May 13, 2026 on Nasdaq, up 0.18%, according to MarketBeat as of 05/13/2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Indivior plc
• Sector/industry: Specialty pharmaceuticals – addiction and mental health treatment
• Headquarters/country: United Kingdom
• Core markets: United States (primary), international
• Key revenue drivers: Addiction treatment medications like Suboxone and Sublocade
• Home exchange/listing venue: NASDAQ (INDV)
• Trading currency: USD

Indivior PLC: core business model

Indivior PLC specializes in developing and commercializing medications for addiction and serious mental health disorders. The company focuses on opioid use disorder, alcohol use disorder, and related conditions, with products like Suboxone sublingual film and Sublocade extended-release injection approved in multiple markets, according to MarketBeat as of 05/13/2026. Headquartered in Slough, UK, with key operations in Richmond, Virginia, Indivior was spun off from Reckitt Benckiser in 2014.

Its model relies on branded therapies backed by clinical data and regulatory protections, targeting high-need areas in behavioral health. The US represents the primary revenue market, making it relevant for American investors tracking Nasdaq-listed names with exposure to healthcare demand.

Main revenue and product drivers for Indivior PLC

Indivior generates revenue mainly from Suboxone and Sublocade, treatments for opioid dependence. Recent quarterly figures showed $317 million in revenue and $0.96 EPS, with a 19.44% net margin for the period ending in early 2026, per MarketBeat as of 05/13/2026. These products drive growth amid rising addiction treatment needs in the US.

Pipeline advancements in mental health therapeutics further support revenue potential, contributing to analyst optimism post-Q1 beat.

Why Indivior PLC matters for US investors

Listed on Nasdaq as INDV, Indivior offers US investors direct access to a leader in addiction medicine, a sector tied to American public health challenges like the opioid crisis. With major operations in Virginia and primary sales in the US, the stock provides exposure to domestic healthcare trends without foreign exchange complexity.

Conclusion

Indivior PLC's Q1 earnings beat and raised 2026 EPS estimates highlight strength in its addiction treatment portfolio amid favorable sector dynamics. Trading at a P/E of 19.67 versus the medical sector's 21.23 as of May 13, 2026 per MarketBeat, the Nasdaq-listed stock remains in focus for US investors eyeing specialty pharma. Ongoing pipeline progress could shape future performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.